|
News For CAT;BMY From The Last 14 Days Check below for free stories on CAT;BMY the last two weeks. |
|
|
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| 05:21 EDT |  | CAT | Caterpillar, Mining Machinery resolve all outstanding issues
Subscribe for More Information |
|
| May 16, 2013 |
| 19:01 EDT |  | CAT | Caterpillar and Mining Machinery Limited announce settlement agreement
Subscribe for More Information |
|
| 16:32 EDT |  | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT |  | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT |  | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 08:55 EDT |  | BMY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT |  | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 05:52 EDT |  | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
|
| May 15, 2013 |
| 11:28 EDT |  | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
| |
| 09:43 EDT |  | BMY | Active equity option families trading on open
Subscribe for More Information |
|
| May 14, 2013 |
| 07:24 EDT |  | BMY | EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 11:48 EDT |  | BMY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 06:30 EDT |  | CAT | Caterpillar, Milwaukee workers' union talks suspended, Reuters says
Subscribe for More Information |
|
| May 9, 2013 |
| 10:17 EDT |  | BMY | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information |
|
| May 8, 2013 |
| 11:43 EDT |  | CAT | Caterpillar sees some 'encouraging signs' in China business
Subscribe for More Information |
|
| 10:33 EDT |  | BMY | Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday. |
|
| May 7, 2013 |
| 18:58 EDT |  | CAT | Caterpillar set to resume talks with union, WSJ says
Subscribe for More Information |
|
| May 6, 2013 |
| 17:03 EDT |  | BMY | Bristol-Myers, Pfizer announce publication of ARISTOTLE trial Bristol-Myers Squibb (BMY) and Pfizer (PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. Based on the results of the subanalysis, the benefits of Eliquis compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers' and patients' quality of INR control. |
|
| 11:19 EDT |  | CAT | Caterpillar shares may offer good entry point, Barron's says Shares of Caterpillar seem to be pricing in a lot of bad news and current levels could prove to be a good entry point for longer term investors, Barron's said over the weekend in its The Trader column.Reference Link |
| |
|
|
|
|